Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of aficamten versus metoprolol in symptomatic obstructive hypertrophic cardiomyopathy
MOH_2023-07-10_012716Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aficamten and metoprolol in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Cytokinetics. Primary endpoint: Primary endpoint not provided. Started Jun 2023; status: active, not recruiting.
02
Drugs
aficamtenmetoprolol
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on MOH_2023-07-10_012716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-10_012716.